Soluble urokinase Plasminogen Activator Receptor (suPAR) levels are predictive of COVID-19 severity : an Italian experience
Copyright © 2022 Elsevier Inc. All rights reserved..
BACKGROUND: The soluble urokinase Plasminogen Activator Receptor (suPAR) has been identified as a reliable marker of COVID-19 severity, helping in personalizing COVID-19 therapy. This study aims to evaluate the correlation between suPAR levels and COVID-19 severity, in relation to the traditional inflammatory markers.
METHODS: Sera from 71 COVID-19 patients were tested for suPAR levels using Chorus suPAR assay (Diesse Diagnostica Senese SpA, Italy). suPAR levels were compared with other inflammatory markers: IL-1β, IL-6, TNF-α, circulating calprotectin, neutrophil and lymphocyte counts, and Neutrophil/Lymphocytes Ratio (NLR). Respiratory failure, expressed as P/F ratio, and mortality rate were used as indicators of disease severity.
RESULTS: A positive correlation of suPAR levels with IL-6 (r = 0.479, p = 0.000), TNF-α (r = 0.348, p = 0.003), circulating calprotectin (r = 0.369, p = 0.002), neutrophil counts (r = 0.447, p = 0.001), NLR (r = 0.492, p = 0.001) has been shown. Stratifying COVID-19 population by suPAR concentration above and below 6 ng/mL, we observed higher levels of circulating calprotectin (10.1 μg/mL, SD 7.9 versus 6.4 μg/mL, SD 7.5, p < 0.001), higher levels of P/F ratio (207.5 IQR 188.3 vs 312.0 IQR 127.8, p = 0.013) and higher mortality rate. Median levels of suPAR were increased in all COVID-19 patients requiring additional respiratory support (Nasal Cannula, Venturi Mask, BPAP and CPAP) (6.5 IQR = 4.9) compared to the group at room air (4.6 IQR = 4.2).
CONCLUSION: suPAR levels correlate with disease severity and survival rate of COVID-19 patients, representing a promising prognostic biomarker for the risk assessment of the disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:242 |
|---|---|
| Enthalten in: |
Clinical immunology (Orlando, Fla.) - 242(2022) vom: 01. Sept., Seite 109091 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Infantino, Maria [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.09.2022 Date Revised 21.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clim.2022.109091 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344642755 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344642755 | ||
| 003 | DE-627 | ||
| 005 | 20231226023240.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clim.2022.109091 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1148.xml |
| 035 | |a (DE-627)NLM344642755 | ||
| 035 | |a (NLM)35944880 | ||
| 035 | |a (PII)S1521-6616(22)00172-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Infantino, Maria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Soluble urokinase Plasminogen Activator Receptor (suPAR) levels are predictive of COVID-19 severity |b an Italian experience |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.09.2022 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: The soluble urokinase Plasminogen Activator Receptor (suPAR) has been identified as a reliable marker of COVID-19 severity, helping in personalizing COVID-19 therapy. This study aims to evaluate the correlation between suPAR levels and COVID-19 severity, in relation to the traditional inflammatory markers | ||
| 520 | |a METHODS: Sera from 71 COVID-19 patients were tested for suPAR levels using Chorus suPAR assay (Diesse Diagnostica Senese SpA, Italy). suPAR levels were compared with other inflammatory markers: IL-1β, IL-6, TNF-α, circulating calprotectin, neutrophil and lymphocyte counts, and Neutrophil/Lymphocytes Ratio (NLR). Respiratory failure, expressed as P/F ratio, and mortality rate were used as indicators of disease severity | ||
| 520 | |a RESULTS: A positive correlation of suPAR levels with IL-6 (r = 0.479, p = 0.000), TNF-α (r = 0.348, p = 0.003), circulating calprotectin (r = 0.369, p = 0.002), neutrophil counts (r = 0.447, p = 0.001), NLR (r = 0.492, p = 0.001) has been shown. Stratifying COVID-19 population by suPAR concentration above and below 6 ng/mL, we observed higher levels of circulating calprotectin (10.1 μg/mL, SD 7.9 versus 6.4 μg/mL, SD 7.5, p < 0.001), higher levels of P/F ratio (207.5 IQR 188.3 vs 312.0 IQR 127.8, p = 0.013) and higher mortality rate. Median levels of suPAR were increased in all COVID-19 patients requiring additional respiratory support (Nasal Cannula, Venturi Mask, BPAP and CPAP) (6.5 IQR = 4.9) compared to the group at room air (4.6 IQR = 4.2) | ||
| 520 | |a CONCLUSION: suPAR levels correlate with disease severity and survival rate of COVID-19 patients, representing a promising prognostic biomarker for the risk assessment of the disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Inflammatory markers | |
| 650 | 4 | |a Respiratory support | |
| 650 | 4 | |a Risk assessment | |
| 650 | 4 | |a suPAR | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Leukocyte L1 Antigen Complex |2 NLM | |
| 650 | 7 | |a Receptors, Urokinase Plasminogen Activator |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 700 | 1 | |a Morena, Lorenza |e verfasserin |4 aut | |
| 700 | 1 | |a Di Pietro, Massimo Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Romanin, Benedetta |e verfasserin |4 aut | |
| 700 | 1 | |a Cimolato, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Rocca, Beatrice Anna Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Tunnera, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Modi, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Tilli, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Grossi, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Lari, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Cerutti, Helena |e verfasserin |4 aut | |
| 700 | 1 | |a Tesi, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Anrò, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Cartocci, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Benucci, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Veneziani, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Casprini, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Manfredi, Mariangela |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical immunology (Orlando, Fla.) |d 1999 |g 242(2022) vom: 01. Sept., Seite 109091 |w (DE-627)NLM098196855 |x 1521-7035 |7 nnns |
| 773 | 1 | 8 | |g volume:242 |g year:2022 |g day:01 |g month:09 |g pages:109091 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clim.2022.109091 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 242 |j 2022 |b 01 |c 09 |h 109091 | ||